Novo Nordisk Investor Presentation - First Nine Months of 2016

Investor presentation First nine months of 2016 Slide 102 Modern insulin and VictozaⓇ comprise around 60% of total sales in the first nine months of 2016 Reported sales split by product segments the first nine months of 2016 New Generation Insulin GLP-1 Haemophilia Other Biopharmaceuticals Modern Insulin Other Diabetes and Obesity Care Growth Hormone Reported sales split by selected key products the first nine months of 2016 Human Insulin Reported currencies Tresiba LevemirⓇ changing diabetes 3% 8% 3% 10% 5% 18% 43% 10% Sales of DKK 82,208 million (+4%) Sales (mDKK) Sales split 2,506 3% 12,999 16% NovoRapidⓇ NovoMixⓇ 14,406 18% 7,886 10% VictozaⓇ 14,649 18% SaxendaⓇ 1,037 1% Diabetes and obesity care¹ 65,122 79% NovoSevenⓇ® 6,940 8% NorditropinⓇ 6,568 8% Biopharmaceuticals¹ 17,086 21% Total¹ 82,208 100% 1 Values are higher than the sum of the total elements listed due to residual values from products not listed novo nordisk

View entire presentation